Dr Jing Chao Discusses Knowledge Gaps and the Future for Biosimilar Insulins

July 5, 2020

We sat down with Jing Chao, MD, an assistant professor of medicine and metabolism, endocrinology and nutrition at the University of Washington in Seattle and one of the lead investigators of this study to discuss the findings of this study as well as how biosimilar insulins could pave the way for increased patient access.

Many physicians are wary about prescribing biosimilars, worrying that they are not as safe and effective as their reference products. Additionally, fears could be worsened as there have disturbing accounts of patients developing serious medical conditions as a result of switching insulin products.

However, study results presented at the American Diabetes Association 80th Scientific Sessions online conference concluded that increased risks of hypo- and hyperglycemia as a result of switching from insulin degludec (iDeg) to another insulin stem from physicians administering inappropriate doses when switching entire insulin products. Investigators believe this is a consequence of physicians having a poor understanding of the pharmacodynamics and pharmacokinetics of iDeg.

We sat down with Jing Chao, MD, an assistant professor of medicine and metabolism, endocrinology and nutrition at the University of Washington in Seattle and one of the lead investigators of this study to discuss the findings of this study as well as how biosimilar insulins could pave the way for increased patient access.

To learn more about the study, read our full coverage of it here.